The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetes
Authors:
Open Access
- 14 June 2022
- journal article
- research article
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 29, 100301
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Insulin secretion abnormalities in exocrine pancreatic sufficient cystic fibrosis patientsJournal of Cystic Fibrosis, 2015
- Glucose-induced electrical activities and insulin secretion in pancreatic islet β-cells are modulated by CFTRNature Communications, 2014
- CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cellsBMC Medicine, 2014
- Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot studyPediatric Diabetes, 2013
- Abnormal endocrine pancreas function at birth in cystic fibrosis ferretsJournal of Clinical Investigation, 2012
- Cystic Fibrosis–Related Diabetes: Current Trends in Prevalence, Incidence, and MortalityDiabetes Care, 2009
- Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose toleranceEuropean Journal of Endocrinology, 1993
- First-Phase Insulin Release in Adult Cystic Fibrosis Patients: Correlation with Clinical and Biological ParametersHormone Research, 1992
- Localization of the cystic fibrosis transmembrane conductance regulator in pancreas.Journal of Clinical Investigation, 1991
- Cystic fibrosis associated islet changes may provide a basis for diabetesVirchows Archiv, 1989